乳腺癌的新辅助治疗.pptVIP

. * Materiale di training ad escliusivo uso interno * * * * * * * * * * * * * * * * * * NSABP B-40: Chemotherapy ± Bevacizumab in Patients with Operable HER2-Negative Breast Cancer OperableBreastCancer R Tissue forBiomarkers SURGERY Tissue forBiomarkers +/- +/- X10 T docetaxelX capecitabine G gemcitabine B bevacizumab NSABP B-40: Benefit of Adding Bevacizumab to Standard Chemotherapy Bear HD et al. Proc ASCO 2011;Abstract LBA1005. Benefit of bev predominant in HR+ and not TNBC patient subgroup pCRbreast (with bev vs without bev): HR+ patients: 23.3 vs 15.2% (p = 0.008) TNBC patients: 51.3 vs 47.3% (p = 0.44) Yes No A If YES, for which duration (choose one)? 2.2% 97.8% 0% Neo Adjuvant Systemic Therapy Is neodjuvant endocrine therapy alone a reasonable option for postmenopausal pts with highly endocrine-responsive disease? 3-4 months 4-8 months Maximal response 15.2% 39.1% 45.7% St Gallen 2011 Grazie! * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * pCR and tpCR Materiale di training ad escliusivo uso interno Materiale di training ad escliusivo uso interno * * * * * * * * * * * * * * * * . LAPATINIB VS TRASTUZUMAB IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE-TAXANE-BASED CHEMOTHERAPY: PRIMARY EFFICACY ENDPOINT ANALYSIS OF THE GEPARQUINTO STUDY (GBG 44) Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching P, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G for the GBG /AGO study group This presentation is the intellectual property of the author/presenter? Contact them for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium - Cancer Therapy and Research Center at UT Health Science Center – December 8-12, 2010 Conclusions from Run-in Phase(N=60) Neutropenia Grade III/ IV in 82% G-CSF made mandatory together with L Treatment